Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AstraZeneca PLC Heart Drug Wins Approval In China-Reuters


Thursday, 29 Nov 2012 06:08am EST 

Reuters reported that AstraZeneca PLC won approval for its new heart drug Brilinta in China, an increasingly important market for the British pharmaceuticals group. Food and Drug Administration has issued an drug import licence for the product, meaning it will now be available for treating patients with acute coronary syndrome in the country, the Company said on November 29, 2012. Brilinta has proved better than the cheaper generic medicine clopidogrel in preventing the recurrence of heart attacks, but its sales to date in markets around the world have been disappointing. 

Company Quote

4344.5
-13.0 -0.30%
12:14pm EDT